Trulieve Cannabis Corp. reported second-quarter 2026 revenue of $271 million, with 94% coming from retail sales, and said it became the first U.S. cannabis company to list on the New York Stock Exchange under the ticker TRLV. Gross margin was 60% and GAAP gross profit was $162 million. Net loss attributable to common shareholders widened to $406 million, or $2.10 per share, driven by a $407 million impact from the Harvest deconsolidation and equity investment. On an adjusted basis, the company posted net income of $20 million, or $0.11 per share, and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, adjusted for certain items) of $98 million, equal to 36% of revenue. Operating cash flow was $53 million in the quarter, while first-half 2026 operating cash flow reached $109 million and free cash flow (operating cash flow minus capital expenditures) totaled $74 million. Trulieve ended the quarter with $325 million in cash, filed applications with the Drug Enforcement Agency (U.S. drug enforcement agency) to register state licensed medical marijuana operations after medical marijuana was moved to Schedule III, completed the deconsolidation of Harvest mixed medical and adult use state operations, and launched a share repurchase program for up to the lesser of $50 million or 8,495,038 subordinate voting shares. The company also began shipping medical cannabis products to licensed independent pharmacies in Georgia, opened four Florida dispensaries in Belleview, Boca Raton, Lutz and Tallahassee, and later added one in Marco Island. CEO Kim Rivers said broader cannabis rescheduling and state program expansion in markets including Georgia and Texas could support future growth.